title: [Medication management: Simvastatin and Amlodipin - a clinically relevant drug-interaction?]
abstract: The clinical relevance of the drug-drug interaction simvastatin and amlodipine is appraised controversially by german simvastatin Summary of Product Characteristics (SPCs) and different drug interaction databases. Results of clinical trials have shown that simultaneous administration of simvastatin and amlodipine can increase simvastatin bioavailability. However, it is unclear whether this increase is associated with a higher risk for adverse drug events. So far there is no evidence that the combination might increase cases of myopathy or rhabdomyolysis. Therefore combined treatment with amlodipine and up to 40 mg simvastatin daily seems clinically justifiable if the patient does not report adverse events. If myopathy or muscle weakness occur, simvastatin dose should be reduced to 20 mg daily or the patient should be switched to pravastatin, fluvastatin or rosuvastatin. The highest approved dose of simvastatin (80 mg) is generally not recommended in new patients because of increased risk of muscle damage.
authors.forename: Jane
authors.initials: J
authors.lastname: Schröder
authors.forename: Lisa
authors.initials: L
authors.lastname: Goltz
authors.forename: Holger
authors.initials: H
authors.lastname: Knoth
mesh_terms: D017311:Amlodipine / Q000008:administration & dosage* / Q000009:adverse effects*; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects; D004347:Drug Interactions; D019317:Evidence-Based Medicine; D006801:Humans; D019821:Simvastatin / Q000008:administration & dosage* / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D000959:Antihypertensive Agents; D017311:Amlodipine; D019821:Simvastatin